CASE REPORT
A Case Report of Dapagliflozin-Induced Nodular Vasculitis
Dapagliflozin İlişkili Nodüler Vaskülit Olgu Sunumu
Received Date : 25 Nov 2020
Accepted Date : 02 Feb 2021
Available Online : 09 Mar 2021
Muhammet KOCABAŞ, Zeliha YARAR, İlker ÇORDAN*, Mustafa CAN, Hatice ÇALIŞKAN BURGUCU, Harun AYDEMİR**, Melia KARAKÖSE, Mustafa KULAKSIZOĞLU, Feridun KARAKURT
Department of Endocrinology and Metabolism, Necmettin Erbakan University Meram Faculty of Medicine, Konya, TURKEY
*Clinic of Endocrinology and Metabolism, Edirne Sultan 1. Murat State Hospital, Edirne, TURKEY
**Department of Rheumatology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, TURKEY
Doi: 10.25179/tjem.2020-80188 - Makale Dili: EN
Turk J Endocrinol Metab. 2021;25:129-132
ABSTRACT
Nodular vasculitis (NV), first described by Montgomery in
1945 for erythema induratum-like lesions, is a rare form of
panniculitis that is particularly localized on the calves. Characterized
by plaques and erythematous nodules, NV may
often show ulceration and draining. It is known as a reactive
disease associated with many causative factors. Several NV
cases due to infectious or non-infectious causative factors
have been reported, but no case of NV due to sodium-glucose
cotransporter-2 inhibitors (SGLT2i) has yet been reported.
In this case report, we presented a case diagnosed
with NV, who presented with tender, erythematous, eroded
plaques with hemorrhagic-purulent discharge on both legs
during treatment with dapagliflozin (an SGLT2i).
Keywords: Nodular vasculitis; dapagliflozin; antinuclear antibodies; sodium-glucose cotransporter-2 inhibitors; diabetes mellitus
ÖZET
İlk olarak 1945 yılında Montgomery tarafından eritema induratum
benzeri lezyonlar için tanımlanmış olan nodüler
vaskülit (NV), özellikle bacaklarda lokalize olan ve nadir görülen
bir pannikülit formudur. NV, plaklarla ve eritematöz
nodüllerle karakterize olup, zaman zaman ülsere ve akıntılı
hâle gelebilir. Birçok nedensel faktörlerle ilişkili reaktif bir
hastalık olarak bilinmektedir. Enfeksiyöz ya da enfeksiyöz
olmayan nedenlere bağlı birçok NV vakası bildirilmiştir,
ancak sodyum glukoz ko-transporter 2 (SGLT2) inhibitörlerine
bağlı bir NV vakası henüz bildirilmemiştir. Bu olgu sunumunda,
dapagliflozin (bir SGLT2 inhibitörü) tedavisi
esnasında her iki bacağında gelişen hassas, eritemli, erode
ve hemorajik-pürülan akıntılı plaklarla başvuran ve NV tanısı
konulan bir olguyu sunduk.
Anahtar Kelimeler: Nodüler vaskülit; dapagliflozin; antinükleer antikorlar; sodyum glukoz ko-transporter 2 inhibitörleri; diabetes mellitus
KAYNAKLAR
- Montgomery RM. A case for diagnosis; dermatophytosis; nodular vasculitis? Arch Derm Syphilol. 1948;57:580.[Crossref] [PubMed]
- Segura S, Pujol RM, Trindade F, Requena L. Vasculitis in erythema induratum of Bazin: a histopathologic study of 101 biopsy specimens from 86 patients. J Am Acad Dermatol. 2008;59:839-851.[Crossref] [PubMed]
- Patterson JW, Brown PC, Broecker AH. Infection-induced panniculitis. J Cutan Pathol. 1989;16:183-193.[Crossref] [PubMed]
- Sakuma H, Niiyama S, Amoh Y, Katsuoka K. Chlamydophila pneumoniae infection induced nodular vasculitis. Case Rep Dermatol. 2011;3:263-267.[Crossref] [PubMed] [PMC]
- Ural I, Erel A, Ozenirler S, Tekin NS, Gurert MA. Nodular vasculitis associated with chronic hepatitis C. J Eur Acad Dermatol Venereol. 2002;16:298-299.[Crossref] [PubMed]
- Park SB, Chang IK, Im M, Lee Y, Kim CD, Seo YJ, Lee JH. Nodular vasculitis that developed during etanercept (Enbrel) treatment in a patient with psoriasis. Ann Dermatol. 2015;27:605-607.[Crossref] [PubMed] [PMC]
- Wolf D, Ben-Yehuda A, Okon E, Naparstek Y. Nodular vasculitis associated with propylthiouracil therapy. Cutis. 1992;49:253-255.[PubMed]
- Misago N, Narisawa Y. Erythema induratum (nodular vasculitis) associated with Crohn's disease: a rare type of metastatic Crohn's disease. Am J Dermatopathol. 2012;34:325-329.[Crossref] [PubMed]
- Gilchrist H, Patterson JW. Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management. Dermatol Ther. 2010;23:320-327.[Crossref] [PubMed]
- Borges AS, Brasileiro A, Apetato M. Nodular vasculitis associated with lung adenocarcinoma. An Bras Dermatol. 2018;93:887-889.[Crossref] [PubMed] [PMC]
- Khachemoune A, Longo MI, Phillips TJ. Nodular vasculitis as a paraneoplastic presentation? Int J Dermatol. 2003;42:639-642.[Crossref] [PubMed]
- Haas B, Eckstein N, Pfeifer V, Mayer P, Hass MD. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes. 2014;4:e143.[Crossref] [PubMed] [PMC]
- Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457-463.[Crossref] [PubMed]
- Powell J, Garland SG. Ertugliflozin: a new option in the SGLT-2 inhibitor market for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2019;53:478-485.[Crossref] [PubMed]
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.[Crossref] [PubMed]
- Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376:2300-2302.[Crossref] [PubMed]
- Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12:711-712.[Crossref] [PubMed]
- To D, Bradshaw S, Lipson J. Case report of empagliflozin-induced cutaneous polyarteritis nodosa. J Cutan Med Surg. 2018;22:516-518.[Crossref] [PubMed]